MDGL
Price
$324.15
Change
-$7.08 (-2.14%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
7.15B
41 days until earnings call
ONC
Price
$270.85
Change
-$1.32 (-0.48%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
32.21B
29 days until earnings call
Ad is loading...

MDGL vs ONC

Header iconMDGL vs ONC Comparison
Open Charts MDGL vs ONCBanner chart's image
Madrigal Pharmaceuticals
Price$324.15
Change-$7.08 (-2.14%)
Volume$3.45K
Capitalization7.15B
BeiGene
Price$270.85
Change-$1.32 (-0.48%)
Volume$2.75K
Capitalization32.21B
MDGL vs ONC Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. ONC commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and ONC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (MDGL: $331.23 vs. ONC: $272.17)
Brand notoriety: MDGL and ONC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 87% vs. ONC: 112%
Market capitalization -- MDGL: $7.15B vs. ONC: $32.21B
MDGL [@Biotechnology] is valued at $7.15B. ONC’s [@Biotechnology] market capitalization is $32.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileONC’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • ONC’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than ONC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish while ONC’s TA Score has 3 bullish TA indicator(s).

  • MDGL’s TA Score: 3 bullish, 5 bearish.
  • ONC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both MDGL and ONC are a bad buy in the short-term.

Price Growth

MDGL (@Biotechnology) experienced а -4.38% price change this week, while ONC (@Biotechnology) price change was +7.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

ONC is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONC($32.2B) has a higher market cap than MDGL($7.15B). ONC YTD gains are higher at: 47.350 vs. MDGL (7.344). ONC has higher annual earnings (EBITDA): -396.44M vs. MDGL (-450.12M). ONC has more cash in the bank: 2.63B vs. MDGL (926M). MDGL has less debt than ONC: MDGL (120M) vs ONC (1.08B). ONC has higher revenues than MDGL: ONC (3.81B) vs MDGL (180M).
MDGLONCMDGL / ONC
Capitalization7.15B32.2B22%
EBITDA-450.12M-396.44M114%
Gain YTD7.34447.35016%
P/E RatioN/AN/A-
Revenue180M3.81B5%
Total Cash926M2.63B35%
Total Debt120M1.08B11%
FUNDAMENTALS RATINGS
MDGL vs ONC: Fundamental Ratings
MDGL
ONC
OUTLOOK RATING
1..100
7677
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
2762
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
4338
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ONC's Valuation (66) in the Biotechnology industry is in the same range as MDGL (69) in the Pharmaceuticals Other industry. This means that ONC’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is somewhat better than the same rating for ONC (62) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than ONC’s over the last 12 months.

ONC's SMR Rating (94) in the Biotechnology industry is in the same range as MDGL (98) in the Pharmaceuticals Other industry. This means that ONC’s stock grew similarly to MDGL’s over the last 12 months.

ONC's Price Growth Rating (38) in the Biotechnology industry is in the same range as MDGL (43) in the Pharmaceuticals Other industry. This means that ONC’s stock grew similarly to MDGL’s over the last 12 months.

ONC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that ONC’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLONC
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 12 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JRS8.240.13
+1.60%
Nuveen Real Estate Income Fund
IJS97.480.29
+0.30%
iShares S&P Small-Cap 600 Value ETF
ECON21.79-0.02
-0.10%
Columbia Res Enh Emerging Econ ETF
RNEM51.29-0.24
-0.47%
First Trust Emerging Markets Eq Sel ETF
JETS20.77-0.36
-1.70%
US Global Jets ETF

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+1.02%
KANT - MDGL
62%
Loosely correlated
+15.57%
ALXO - MDGL
56%
Loosely correlated
-4.90%
ZNTL - MDGL
51%
Loosely correlated
-12.15%
CGEM - MDGL
50%
Loosely correlated
-5.61%
TSVT - MDGL
50%
Loosely correlated
-0.20%
More

ONC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ONC has been loosely correlated with ZLAB. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ONC jumps, then ZLAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONC
1D Price
Change %
ONC100%
+1.79%
ZLAB - ONC
43%
Loosely correlated
-3.08%
MDGL - ONC
42%
Loosely correlated
+1.02%
WXXWY - ONC
37%
Loosely correlated
+4.05%
AXON - ONC
37%
Loosely correlated
-1.68%
GOSS - ONC
35%
Loosely correlated
-5.98%
More